‘Phantom recall’ dogs J&J at congressional hearing
June 1, 2010Manufacturing and Production Johnson & Johnson, McNeil, Tylenol, manufacturing compliance
Johnson & Johnson subsidiary McNeil Consumer Healthcare initiated a recall of its painkiller Motrin (ibuprofen) last year without informing the …
Contract research news in brief
June 1, 2010Research and Development CRO, NIB
Irish contract research organisation ICON plc has acquired Timaq Medical Imaging, a Swiss provider of imaging services to pharmaceutical and …
Novo withdraws insulins in Greece price protest
May 31, 2010Sales and Marketing Greece, pricing
Insulin manufacturer Novo Nordisk says it will withdraw its modern insulin products from Greece in protest at a 25% price …
Abbott and Daiichi Sankyo acclaimed in great places to work survey
May 31, 2010Business Services Abbott, Daiichi Sankyo
The Great Place to Work Institute has named Abbott as one of the Top 50 Best Workplaces in the UK, …
Inspra performs strongly in heart failure patients
May 28, 2010Research and Development, Sales and Marketing Inspra, Pfizer, chronic heart failure, heart failure
Pfizer is to end a clinical trial of Inspra early because of signs that it significantly cuts the risk of …
Woolley Pau expands client services department
May 28, 2010Medical Communications Woolley Pau, appointment, medical communications
Woolley Pau has appointed Sarah Philp as a senior account director within its client services department. She has 10 years’ …
Napp rises in Best Companies to Work For survey
May 28, 2010Business Services Napp, careers, recruitment
Napp Pharmaceutical Holdings has risen to position 5 in the latest Sunday Times Top 100 Best Companies to Work For, …
Edelman bags the FT’s Stefan Stern
May 27, 2010Medical Communications Edelman, appointment, medical communications
PR agency Edelman has appointed Stefan Stern director of strategy.He will provide senior counsel to the agency’s clients across all …
Pfizer R&D head exits for AstraZeneca
May 27, 2010Research and Development AstraZeneca, Pfizer, appointment, research and development
One of Pfizer’s two heads of research and development Martin Mackay is to leave the company for rivals AstraZeneca. Only …
Slow recovery expected for epilepsy market
May 27, 2010Sales and Marketing Datamonitor, Keppra, UCB, epilepsy
The global market for epilepsy treatments is expected to make a slow recovery after a wave of patent expiries from …
Digital Pharma: Byte-sized roundup
May 27, 2010Medical Communications Twitter, digi game, disease awareness campaigns, doctors.net
This week’s roundup includes the launch of Boehringer Ingelheim’s digital diabetes hub, J&J expands Twitter use, continued international expansion at …
Sanofi signs biomedical collaboration with MIT
May 27, 2010Research and Development MIT, Sanofi-Aventis, academia, biomedical
Sanofi-Aventis has formed a strategic alliance with the Centre for Biodmedical Innovation at the Massachusetts Institute of Technology. The alliance, …
J&J faces FDA scrutiny for another manufacturing unit
May 27, 2010Manufacturing and Production Advanced Sterilization Products, Ethicon, J&J, JJ, McNeil, manufacturing compliance
Another Johnson & Johnson subsidiary has come under scrutiny by FDA for failing to meet quality standards in its manufacturing. …
Genzyme confirms details of consent decree and $175m fine
May 27, 2010Manufacturing and Production Cerezyme, Fabrazyme, Genzyme, Lumizyme, Thyrogen, manufacturing compliance
Genzyme’s predictions on the penalties levied for the ongoing problems at its manufacturing facility in Allston Landing have been confirmed, …
FDA approves Genzyme’s Lumizyme
May 27, 2010Sales and Marketing Genzyme, Lumizyme, Myozyme, Pompe disease
US biotech Genzyme is celebrating FDA approval of its late-onset treatment for Pompe disease Lumizyme. The green light to market …
Roche forms translational medicine research hub
May 26, 2010Research and Development Roche, Switzerland, academic research, translational
Roche is linking up with Basel’s university and university hospital in a ‘strategic alliance’ that will establish and manage what …
NICE rejects Bayer’s liver cancer drug
May 26, 2010Sales and Marketing NICE, Nexavar, patient access scheme
Bayer’s liver cancer drug Nexavar has been rejected by NICE after it deemed the drug too costly for a marginal …
Full steam ahead for NHS boards
May 26, 2010Monitor, NHS, government
The government is setting up new NHS boards that will act independently to allocate resources and oversee the commissioning of …
Abbott starts head-to-head MS trial
May 25, 2010Research and Development, Sales and Marketing Abbott, Avonex, Biogen, Gilena, daclizumab
Abbott has started enrolment for a phase III trial of daclizumab, a once-monthly injection for relapsing-remitting multiple sclerosis that it …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
